Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport

Atwal, 2011, A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo, Sci. Transl. Med., 3, 84ra43, 10.1126/scitranslmed.3002254

Ben Halima, 2016, Specific inhibition of beta-secretase processing of the Alzheimer disease amyloid precursor protein, Cell Rep., 14, 2127, 10.1016/j.celrep.2016.01.076

Boissart, 2013, Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screening, Transl. Psychiatry, 3, 10.1038/tp.2013.71

Brockhaus, 1998, Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling, Neuroreport, 9, 1481, 10.1097/00001756-199805110-00043

Brown, 1998, Functions of lipid rafts in biological membranes, Annu. Rev. Cell Dev. Biol., 14, 111, 10.1146/annurev.cellbio.14.1.111

Cai, 2001, BACE1 is the major beta-secretase for generation of Abeta peptides by neurons, Nat. Neurosci., 4, 233, 10.1038/85064

Chambers, 2009, Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling, Nat. Biotechnol., 27, 275, 10.1038/nbt.1529

Chang, 2011, Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice, FASEB J., 25, 775, 10.1096/fj.10-167213

Cirrito, 2008, Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo, Neuron, 58, 42, 10.1016/j.neuron.2008.02.003

Evin, 2016, Future therapeutics in Alzheimer's disease: development status of BACE inhibitors, BioDrugs, 30, 173, 10.1007/s40259-016-0168-3

Farzan, 2000, BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein, Proc. Natl. Acad. Sci. U. S. A., 97, 9712, 10.1073/pnas.160115697

Fishman, 1987, Receptor-mediated transcytosis of transferrin across the blood-brain barrier, J. Neurosci. Res., 18, 299, 10.1002/jnr.490180206

Freskgard, 2017, Antibody therapies in CNS diseases, Neuropharmacology, 120, 38, 10.1016/j.neuropharm.2016.03.014

Friden, 1991, Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier, Proc. Natl. Acad. Sci. U. S. A., 88, 4771, 10.1073/pnas.88.11.4771

Ghosh, 2012, Developing beta-secretase inhibitors for treatment of Alzheimer's disease, J. Neurochem., 120, 71, 10.1111/j.1471-4159.2011.07476.x

Gruninger-Leitch, 2002, Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases, J. Biol. Chem., 277, 4687, 10.1074/jbc.M109266200

Hardy, 1992, Alzheimer's disease: the amyloid cascade hypothesis, Science, 256, 184, 10.1126/science.1566067

Hock, 2003, Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease, Neuron, 38, 547, 10.1016/S0896-6273(03)00294-0

Hong, 2000, Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor, Science, 290, 150, 10.1126/science.290.5489.150

Jacobsen, 2014, Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice, J. Neurosci., 34, 11621, 10.1523/JNEUROSCI.1405-14.2014

Kornacker, 2005, An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme, Biochemistry, 44, 11567, 10.1021/bi050932l

Laird, 2005, BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions, J. Neurosci., 25, 11693, 10.1523/JNEUROSCI.2766-05.2005

Lu, 2016, Characterization of a sensitive mouse Abeta40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice, Bioanalysis, 8, 1067, 10.4155/bio-2016-0003

May, 2011, Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor, J. Neurosci., 31, 16507, 10.1523/JNEUROSCI.3647-11.2011

Mcconlogue, 2007, Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice, J. Biol. Chem., 282, 26326, 10.1074/jbc.M611687200

Ottaviani, 2015, Importance of critical micellar concentration for the prediction of solubility enhancement in biorelevant media, Mol. Pharm., 12, 1171, 10.1021/mp5006992

Popp, 2009, Site-specific protein labeling via sortase-mediated transpeptidation, Curr. Protoc. Protein Sci., 10.1002/0471140864.ps1503s56

Quartino, 2014, Population pharmacokinetic and pharmacodynamic analysis of plasma Abeta40 and Abeta42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers, Clin. Pharmacol. Drug Dev., 3, 396, 10.1002/cpdd.130

Rajendran, 2008, Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting, Science, 320, 520, 10.1126/science.1156609

Rashidian, 2013, Enzymatic labeling of proteins: techniques and approaches, Bioconjug. Chem., 24, 1277, 10.1021/bc400102w

Roberts, 1993, Receptor-mediated endocytosis of transferrin at the blood-brain barrier, J. Cell Sci., 104, 521, 10.1242/jcs.104.2.521

Tolcher, 2012, Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors, J. Clin. Oncol., 30, 2348, 10.1200/JCO.2011.36.8282

Tung, 2002, Design of substrate-based inhibitors of human beta-secretase, J. Med. Chem., 45, 259, 10.1021/jm0155695

Turner, 2005, Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase), Biochemistry, 44, 105, 10.1021/bi048106k

Yan, 2016, Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs, Transl. Neurodegener., 5, 13, 10.1186/s40035-016-0061-5

Yu, 2011, Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target, Sci. Transl. Med., 3, 84ra44, 10.1126/scitranslmed.3002230